Developmental Medicine & Child Neurology
Volume 67, Issue 4 pp. 426-427
COMMENTARY

Neurocognitive therapies for monogenic conditions: Time for a new approach?

Jonathan M. Payne, 

Corresponding Author

Jonathan M. Payne

Murdoch Childrens Research Institute, Brain and Mind, Parkville, Victoria, Australia

Search for more papers by this author
First published: 11 October 2024
https://doi.org/10.1111/dmcn.16129
Citations: 1

This commentary is on the original article by Ottenhoff et al. on pages 537–549 of this issue.

Abstract

This commentary is on the original article by Ottenhoff et al. on pages 537–549 of this issue.

DATA AVAILABILITY STATEMENT

Not required.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.